Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Payables (2016 - 2025)

Gsk has reported Payables over the past 10 years, most recently at $24.4 billion for Q4 2025.

  • Quarterly results put Payables at $24.4 billion for Q4 2025, up 7.72% from a year ago — trailing twelve months through Dec 2025 was $24.4 billion (up 7.72% YoY), and the annual figure for FY2025 was $24.4 billion, up 7.72%.
  • Payables for Q4 2025 was $24.4 billion at Gsk, up from $22.7 billion in the prior quarter.
  • Over the last five years, Payables for GLAXF hit a ceiling of $28.5 billion in Q4 2021 and a floor of $22.7 billion in Q4 2024.
  • Median Payables over the past 5 years was $23.7 billion (2022), compared with a mean of $24.5 billion.
  • Biggest five-year swings in Payables: grew 10.38% in 2021 and later decreased 16.85% in 2022.
  • Gsk's Payables stood at $28.5 billion in 2021, then decreased by 16.85% to $23.7 billion in 2022, then dropped by 2.34% to $23.2 billion in 2023, then dropped by 1.98% to $22.7 billion in 2024, then increased by 7.72% to $24.4 billion in 2025.
  • The last three reported values for Payables were $24.4 billion (Q4 2025), $22.7 billion (Q4 2024), and $23.2 billion (Q4 2023) per Business Quant data.